2 Bridge joins Normec

2 Bridge was founded in 2013 and can look back on an impressive growth trajectory. The strategic partnership enhances Normec’s capabilities in offering comprehensive solutions in the life sciences sector. The current management, including co-CEOs Tomas van Dyck and Ann Meulemans, will remain actively involved to ensure continuity and to drive future growth.

Joep Bruins, founder and CEO of Normec, expressed his excitement: “We are delighted to welcome 2 Bridge to the Normec family. This acquisition is a pivotal step in expanding our service offerings in the life sciences sector and aligns perfectly with our vision. 2 Bridge’s expertise, network and their strong track record in drug development, especially via their integrated and agile Tiger Team approach, will be invaluable to our clients.”

Vincent Bremmer Managing Director Healthcare Normec, added: “We are impressed with the rapid development of 2 Bridge and are happy to welcome them to the Healthcare division, The addition of 2 Bridge is completely in line with the Healthcare strategy for our life sciences clients. It will enable us to improve our overall Belgian services offering to the various parts of the value chain; from services in the discovery, development- to the production & distribution- and finally product release phase through 2 Bridge, Advipro, and Farma Consulting.”

Ann Meulemans, co-CEO of 2 Bridge: “In this partnership we will bring in our strong network and knowledge of the ecosystem to support the expansion of Normec’s healthcare division and bring in the expertise on all different aspects needed to perform drug discovery, drug development and company building.”

Tomas Van Dyck, co-CEO of 2 Bridge, commented : “The partnership with a financially solid group as Normec, will allow 2 Bridge to continue to invest in its growth and will also enable us to grow as an organization offering further development opportunities for our people as part of Normec family. We look forward to growing 2 Bridge together.”

This strategic partnership reinforces Normec’s commitment to strategic growth and providing high-quality, reliable services across various industries. By integrating 2 Bridge’s drug development expertise, Normec further solidifies its position as a comprehensive service provider in the life sciences sector.

Normec were advised on this transaction by KPMG (financial and tax) and Quinz (legal). 2 Bridge were advised by LDS Advisory (financial and tax) and Argo (legal).

Contact info:

Normec
Frederik Bernoski, General Counsel frederik.bernoski@normecgroup.com

Mike de Groot, Chief Investment Officer mike.de.groot@normecgroup.com

2 Bridge

Ann Meulmans, co-CEO, ann.meulemans@2bridge.be

Tomas Van Dyck, co-CEO, tomas.vandyck@2bridge.be